US20110150920A1 - Allergy Vaccines Containing Hybrid Polypeptides - Google Patents
Allergy Vaccines Containing Hybrid Polypeptides Download PDFInfo
- Publication number
- US20110150920A1 US20110150920A1 US12/954,821 US95482110A US2011150920A1 US 20110150920 A1 US20110150920 A1 US 20110150920A1 US 95482110 A US95482110 A US 95482110A US 2011150920 A1 US2011150920 A1 US 2011150920A1
- Authority
- US
- United States
- Prior art keywords
- allergens
- rphl
- hybrid
- allergen
- phl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 69
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 69
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 69
- 229960005486 vaccine Drugs 0.000 title abstract description 7
- 206010020751 Hypersensitivity Diseases 0.000 title description 20
- 208000026935 allergic disease Diseases 0.000 title description 19
- 230000007815 allergy Effects 0.000 title description 19
- 230000002009 allergenic effect Effects 0.000 claims abstract description 49
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 42
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 39
- 239000012634 fragment Substances 0.000 claims abstract description 22
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 18
- 239000002157 polynucleotide Substances 0.000 claims abstract description 18
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 150000001413 amino acids Chemical class 0.000 claims abstract description 8
- 239000013566 allergen Substances 0.000 claims description 109
- 229960004784 allergens Drugs 0.000 claims description 76
- 238000012360 testing method Methods 0.000 claims description 28
- 230000000172 allergic effect Effects 0.000 claims description 21
- 208000010668 atopic eczema Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 241000746983 Phleum pratense Species 0.000 claims description 15
- 239000013574 grass pollen allergen Substances 0.000 claims description 15
- 230000004927 fusion Effects 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 9
- 241000196324 Embryophyta Species 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 230000001900 immune effect Effects 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 239000002955 immunomodulating agent Substances 0.000 claims 4
- 208000001718 Immediate Hypersensitivity Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 38
- 229940046528 grass pollen Drugs 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 18
- 239000000203 mixture Substances 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 229940030577 timothy grass pollen extract Drugs 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000003053 immunization Effects 0.000 description 11
- 238000002649 immunization Methods 0.000 description 11
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- 238000009169 immunotherapy Methods 0.000 description 8
- 239000003656 tris buffered saline Substances 0.000 description 8
- 206010070834 Sensitisation Diseases 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000926206 Homo sapiens Putative glutathione hydrolase 3 proenzyme Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102100034060 Putative glutathione hydrolase 3 proenzyme Human genes 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- 241000209510 Liliopsida Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000209504 Poaceae Species 0.000 description 2
- 206010048908 Seasonal allergy Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229940074608 allergen extract Drugs 0.000 description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 239000003659 bee venom Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229910001679 gibbsite Inorganic materials 0.000 description 2
- 230000000774 hypoallergenic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 201000004338 pollen allergy Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000024664 tolerance induction Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 108010061629 Dermatophagoides pteronyssinus antigen p 1 Proteins 0.000 description 1
- 108010061608 Dermatophagoides pteronyssinus antigen p 2 Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013575 birch pollen allergen Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000013573 pollen allergen Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Definitions
- Type I allergy is a genetically determined hypersensitivity disease affecting almost 500 million individuals worldwide. Immediate symptoms (allergic rhinoconjunctivitis, asthma, anaphylactic shock) as well as late symptoms (atopic dermatitis, certain forms of allergic asthma bronchiale) are based on the recognition of allergens by IgE antibodies. Immediate symptoms result from the allergen-induced crosslinking of effector cell-bound IgE and the subsequent release of biological mediators (e.g., histamine, leukotrienes) whereas late symptoms can be caused by IgE-mediated presentation of allergens to T cells and eosinophil activation.
- biological mediators e.g., histamine, leukotrienes
- allergen-specific immunotherapy is based on the systemic administration of allergens to patients in order to induce allergen-specific “unresponsiveness” (Noon, Lancet 1911, 1: 1572-1573; Bousquet et al. (1998) J Allergy Clin Immunol 102: 558-562; Durham and Till (1998) J. Allergy Clin. Immunol. 102, 157-164).
- allergen extracts consist of allergens and non-allergenic components which are difficult to standardize.
- the invention therefore relates to a hybrid polypeptide comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein.
- any polypeptide may be used in the hybrid polypeptide which may be involved in vaccination.
- the polypeptide may be derived from viruses such as HI, HC-viruses, bacteria, tumor antigens or plant allergens.
- the allergenic proteins from which the hybrid polypeptide is derived may preferably be a plant allergen.
- the different allergenic proteins may be derived from a common source such as the pollens of a certain plant species.
- Several different allergenic proteins contained in the allergen source may be identified and used for the preparation of the hybrid polypeptide of the invention.
- the present invention encompasses also a hybrid polypeptide comprising sequences derived from allergenic proteins from different sources.
- allergenic proteins or fragments thereof comprises also modifications of the allergens wherein the sequence of the naturally occurring allergen has been slightly modified by substitutions of single amino acids or nucleotides whereby the allergenic potential has been substantially maintained.
- allergenic proteins may be major grass pollen, mite, bee venom or animal hair dander allergens.
- Specific examples of allergenic proteins are the group 1, group 2, group 4, group 5 group 6, group 11, group 12 and group 13 allergens of major grass pollen, Der p 1 and Der p 2 (mite), phospholipase from bee venom and Fel d 1 (cat).
- the hybrid polypeptide comprises at least one complete allergenic protein. It may also comprise two different complete allergenic proteins. It is not only possible to combine different groups of allergenic grass pollen but also to combine allergenic proteins derived from different sources. In a particular embodiment all sequences of the hybrid polypeptide derived from allergenic proteins represent complete allergenic proteins.
- the hybrid polypeptide comprises at least one fragment of an allergenic protein wherein the fragment consists of at least eight consecutive amino acids of the respective allergenic protein.
- the fragment consists of at least 12, more preferably of at least 20 and most preferably of at least 30 consecutive amino acids of the respective allergenic proteins.
- all amino acid sequences derived from allergenic proteins are fragments of at least eight consecutive amino acids of the respective allergenic proteins from which they are derived. The preferred length of these fragments is at least 12, more preferably at least 20, most preferably at least 30 consecutive amino acids of the respective allergenic protein.
- the hybrid polypeptide has an allergic activity which is lower than the allergenic activity of each of the allergenic proteins from which the hybrid polypeptide is derived.
- the allergenic activity of the hybrid polypeptide is less than 50% of that of each of the allergenic proteins from which the hybrid polypeptide is derived.
- the hybrid polypeptide has substantially no allergenic activity.
- the allergenic activity of a sample is determined by determining the IgE antibodies which are induced in a test animal upon application of the sample.
- the allergenic activity is preferably defined in suitable in vitro or in vivo tests.
- a preferred in vitro test is the basophil histamine release assay as described in Vrtala et al., J. Clin. Invest. 1997, 99, pp. 1673-1681.
- the allergenic activity is determined in a skin test as described in van Hage-Hamsten et al. J. Allergy Clin. Immunol. 1999, 104, pp. 969-977 or in Pauli et al. Clin. Exp. Allergy 2000, 30, pp. 1076-1084.
- the hybrid polypeptide comprises two portions which are derived from two different allergenic proteins.
- the hybrid polypeptide of the invention may comprise three, four, five or even more portions each of which is derived from a different allergenic protein.
- the hybrid polypeptide of the invention does not necessarily consist only of amino acid sequences derived from allergenic proteins. It is possible that artificial sequences (e.g. spacer sequences) are inserted between the units representing sequences from different allergenic proteins. It is also possible that the amino acid sequences of the naturally occurring allergenic proteins are modified, e.g. by genetic engineering to introduce mutations which reduce the allergenic activity of the fragment. It is also preferred that the hybrid polypeptide comprises a “tag” sequence which facilitates the purification of the hybrid polypeptide upon expression in a host cell. An example of a “tag” is the hexahistidine tag which allows purification by Ni 2+ chelate chromatography. Other tags are known in the art.
- the hybrid polypeptide of the invention may be prepared by several methods.
- the polypeptide is prepared by expressing a polynucleotide in a host cell.
- the host cell may be a procaryotic or a eucaryotic cell. If procaryotic cells are used the host is preferably E. coli . Examples of eucaryotic cells are yeast, insect cells or cell lines like CHO cells.
- After introducing a suitable polynucleotide encoding the polypeptide of the invention into a host cell the host cell is cultured under conditions such that the polypeptide is expressed in the cell.
- the polypeptide may be secreted by the cell or accumulate inside the cell. Known purification methods can be used to recover the hybrid polypeptide from the cell or from the culture medium.
- the invention also encompasses the preparation of the hybrid polypeptide by chemical synthesis such as solid phase synthesis.
- the invention further concerns a polynucleotide encoding a hybrid polypeptide according to the invention. Due to the degeneracy of the genetic code many different polynucleotide molecules may encode a single polypeptide.
- the polynucleotide of the invention preferably is an expression construct for obtaining the polypeptide after expression in host cells.
- the expression construct may further comprise components which are generally known in the art such as promoter sequences, genes encoding resistance factors against antibiotics, a replication origin etc.
- the invention further relates to a cell transfected or transformed with a polynucleotide of the invention.
- the cell may be a eucaryotic cell or a procaryotic cell.
- Eucaryotic cells may be transfected by a method known per se such as calcium phosphate mediated transfection, electroporation, lipofection etc.
- the invention further relates to a pharmaceutical composition containing a polypeptide, polynucleotide or a cell according to the invention.
- the pharmaceutical composition may further contain a pharmaceutically acceptable carrier or diluent such as a buffer or salt solution.
- a pharmaceutically acceptable carrier or diluent such as a buffer or salt solution.
- the pharmaceutical composition of the invention is a vaccine composition.
- the pharmaceutical composition further contains an adjuvant such as Al(OH) 3 .
- the invention also relates to a method for the preparation of a hybrid polypeptide of the invention.
- the method comprises providing a polynucleotide encoding a hybrid polypeptide, introducing said polynucleotide into a host cell, culturing the host cell thus obtained under conditions such that the hybrid polypeptide is expressed, and recovering the expression product from the cell.
- the polynucleotide may be prepared by methods known in the art, it is preferred that PCR technology is used to prepare the polynucleotide encoding the hybrid polypeptide.
- the invention further concerns the use of a hybrid polypeptide, of a polynucleotide or of a cell of the invention for the preparation of a medicament for the treatment of an allergic disorder.
- Such a medicament may be composed of the polynucleotide encoding a hybride vaccine which can be used directly for DNA-based vaccination against Type I allergy.
- the recombinant or synthetic hybrid polypeptide may be used to prepare formulations for the oral, sublingual or parenteral treatment of Type I allergic disorders as they are now routinely used for immunotherapy. Examples are formulations for sublingual immunotherapy or adjuvant bound hybrid polypeptides for injection immunotherapy.
- Possible applications comprise also cell based forms of immunotherapy which may be based on e.g., dendritic cells or other antigen presenting cells. Those cells are transformed and express the antigen in vivo. Preferably autologous cells transformed with suitable vectors are used.
- One mode of applications may be the subcutaneous injection of adjuvant-bound hybrid polypeptides.
- Another possibility is the oral or nasal administration of the hybrid polypeptide in order to induce immunological tolerance or anergy against the components of the hybrid polypeptides.
- All these possible formulations can be prepared according to rules (dosage, adjuvants, schemes of administration) which are known to the person skilled in the art.
- the invention also relates to the use of a hybrid polypeptide, of a polynucleotide, or of a cell of the invention for the preparation of a medicament for prophylactic vaccination or tolerance induction.
- Prophylactic administration of hybride polypeptides means the administration of the polypeptide to individuals, preferentially children, who do not yet suffer from Type I allergy in order to induce a state of immunological tolerance, anergy or non-responsiveness, or a protective immunity against the components of the hybrid vaccine. This may be achieved by the various protocols outlined for treatment of an established allergic disorder.
- the prophylactic treatment may be performed with hybrid polypeptides consisting of hybride polypeptides or the polynucleotides coding for the hybrid polypeptides as outlined before.
- the invention relates to the use of a hybrid polypeptide of the invention for the detection of antibodies against an allergenic protein in a sample.
- the antibody may be an IgM, IgE, IgG or IgA antibody.
- the concentration of the antibody may be determined from a sample which has been obtained from a body fluid.
- the sample may be derived from animals or humans.
- Such tests may use a solid phase-immobilized hybrid polypeptide or the hybrid polypeptide in the fluid phase. Examples for such tests may be ELISA tests. Westernblotting tests or any other test where the hybrid polypeptide is immobilized to bind specific antibodies out from the test sample.
- the hybrid polypeptide is added directly to the antibody-containing fluid in order to adsorb specific antibodies as e.g., is done for competitive immunological assays.
- the polypeptide of the invention may also be used for cellular tests such as a T-cell proliferation test, mediator release test etc.
- the hybridpolypeptide may be exposed to various types of cells in order to elicit measurable responses. Such responses may comprise the release of histamine or other mediators (e.g., leukotriens, serotonine, ECP) in the case of allergic effector cells (e.g., basophils mast cells, eosinophils).
- the proliferation or death e.g., apoptosis
- Such cells may be T cells.
- hybrid polypeptides may be used to induce the release of cytokines or other immunologically relevant substances (e.g., from T cells) that can be measured. Furthermore, they may be used for antigen presentation assays. The hybrid polypeptide of the invention may also be used for diagnostic screening purposes. Hybrid polypeptides may be also used for in vivo provocation testing. Such tests may comprise skin testing (e.g., skin prick or intradermal testing), nasal provocation testing, all forms of food challenge testing or bronchial provocation testing.
- skin testing e.g., skin prick or intradermal testing
- nasal provocation testing e.g., all forms of food challenge testing or bronchial provocation testing.
- hybrid polypeptides can contain epitopes of unrelated allergens they may be used for diagnostic screening tests (in vitro, in vivo as outlined above) in order to detect sensitization or unresponsiveness against one of the components of the hybrid polypeptide. This may allow to provide the physician with a diagnostic test which is suited to screen for sensitized patients in a fast way.
- diagnostic tests e.g., Phadiatop, Pharmacia, Uppsala, Sweden
- Grasses are also important allergen sources because of their worldwide distribution and heavy pollen production. They contain a variety of different allergenic components which occur as crossreactive allergens in different monocots. The inventors demonstrated that it is possible to generate by recombinant DNA technology hybrid allergens which consist of immunologically unrelated allergens and their epitopes.
- Both, the rPhl p 2/Phl p 6 hybrid and the rPhl p 6/Phl p 2 hybrid preserved the relevant B and T cell epitopes of the components.
- the giant consisting of all 4 allergens also contained the relevant epitopes of the single components.
- hybrid allergen approach will open new avenues for diagnosis and treatment of Type I allergy.
- Hybrids consisting of the most frequently recognized allergens with preserved epitopes represent candidate molecules for in vitro as well as in vivo allergy screening tests.
- the giant described in the present application will likely identify more than 95% of timothy grass pollen allergic patients when used for diagnosis, because it resembles most of the relevant IgE epitopes present in natural timothy grass pollen extract. Molecules such as the giant can be produced also for other allergen systems (e.g., mite allergy).
- the advantage of using hybrid allergens for diagnosis is that they can be produced in a well controlled manner. In contrast to natural allergen extracts, which consist of a difficult to standardize mixture of allergens and non-allergenic materials, hybrid allergens will contain the relevant epitopes in a well defined ratio.
- Recombinant hybrid allergens can also be used for immunotherapy. They can either be composed of the biologically active components or of hypoallergenic allergen units. Hybrid allergens covering frequent co-sensitization patterns may then be used for the treatment of allergies to complex allergen sources, e.g., grass pollen allergy because they resemble the relevant epitopes of the complete extract. Since the hybrid allergens consist of defined components it will be possible to produce well defined formulations for vaccination treatment. Hybrid allergens produced out of hypoallergenic variants will be tolerated in high doses and thus can be used like vaccines regularly used for prevention of viral infections. In this respect it may be considered to use hybrid allergens containing the epitopes of the most relevant allergens for prophylactic vaccination or tolerance induction even in not yet sensitized individuals.
- Table 1 shows the percentage inhibition of IgE binding to recombinant Phl p 2 and Phl p 6 achieved after preadsorption of sera from 20 patients with the hybrid allergens (rPhl p 2/rPhl p 6, rPhl p 6/rPhl p 2) or the recombinant allergens (rPhl p 2, rPhl p 6).
- Table 2 shows the percentage inhibition of IgE binding to recombinant Phl p 1, Phl p 5, and Bet v 1 achieved after preadsorption of sera from 20 patients with the hybrid allergen rPhl p 5/rPhl p 1 or the recombinant allergens (rPhl p 1, rPhl p 5, and rBet v 1).
- ELISA plate-bound allergens A: rPhl p 2 and rPhl p 6; B: rPhl p 1 and rPhl p 5) were preincubated with mouse antisera (mouse anti-rP2-P6, anti-rP6-P2, anti-rPhl p 2, anti-rPhl p 6, anti-rP5-P1, anti-rPhl p 1, anti-rPhl p 5. The percentages inhibition of IgE binding obtained for 4 grass pollen allergic patients are displayed.
- FIG. 1 shows the frequency of co-sensitization to timothy grass pollen allergens rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6 as determined in a population of 110 grass pollen allergic patients.
- FIG. 2 outlines the construction of hybrid vaccines.
- the fusion of the two genes (e.g. Phl p 5, Phl p 1) is mediated by a two-step PCR reaction, creating overlapping ends in the first PCR reaction followed by the amplification of both sequences in a second PCR step.
- FIG. 3 shows the result of example 3.
- Purified timothy grass pollen allergens (rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6) and hybrids of them (rPhl p 5/rPhl p 1, rPhl p 2/rPhl p 6, and rPhl p 6/rPhl p 2) were loaded on a SDS polyacrylamide gel and stained with Coomassie brilliant blue. Molecular weights are displayed at the left margin.
- FIG. 4 (A) a purified recombinant hybrid consisting of Phl p 6/Phl p 2/Phl p 5/Phl p 1 was dotted on nitrocellulose filters.
- row (B) rPhl p 2 (lane 1,3,4, and 5) and rPhl p 5 (lane 2) was immobilized. Filters were incubated with rabbit antisera against rPhl p 1 (lane 1), rPhl p 2 (lane 2), rPhl p 5 (lane 3), and rPhl p 6 (lane 4). The filter in lane 5 was exposed to a mouse monoclonal anti-His-tag antibody.
- FIGS. 5 to 7 show that recombinant hybrid molecules induce stronger IgG 1 antibody responses in mice than the individual components or mixtures thereof.
- FIG. 5 ELISA plate-bound purified recombinant allergens (A: rPhl p 2; B: rPhl p 6; C: rPhl p 1; D: rPhl p 5) were incubated with sera from mice (8 mice per group) which had been immunized with the hybrid molecules (rP2-P6, rP6-P2, rP5-P1), the individual recombinant allergens (rPhl p 1, rPhl p 2, rPhl p 5, rPhl p 6), or with timothy grass pollen extract as indicated on the x-axis.
- Mean IgG 1 levels of sera collected 4 and 8 weeks after immunization correspond to the OD values displayed on the y-axis.
- FIG. 6 ELISA plate-bound purified recombinant allergens (rPhl p 1, rPhl p 2, rPhl p 5, rPhl p 6) were incubated with sera from mice (8 mice per group) which had been immunized with (A) the giant molecule or the individual recombinant allergens rPhl p 1, rPhl p 2, rPhl p 5, rPhl p 6, and with (B) the giant molecule or an equimolar mixture of rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6 as indicated on the x-axis.
- Mean IgG 1 levels of sera collected 4 and 8 weeks after immunization correspond to the OD values displayed on the y-axis.
- FIG. 7 The ELISA plate-bound giant (A), and timothy grass pollen extract (B) were incubated with sera from mice (8 mice per group) which had been immunized with the giant or timothy grass pollen extract as indicated on the x-axis. Mean IgG 1 levels of sera collected 4 and 8 weeks after immunization correspond to the OD values displayed on the y-axis.
- Grasspollen contain a variety of immunologically distinct and related allergens. These components are recognized at different frequencies and intensities. Recombinant timothy grass pollen allergens, rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6, were previously identified as the most important components which resemble most of the IgE epitopes of natural grass pollen extracts (Niederberger et al. (1998) IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J Allergy Clin Immunol 101: 258-264).
- FIG. 1 The results of the evaluation of co-sensitizations in 110 grass pollen allergic patients to combinations of the recombinant timothy grass pollen allergens are displayed in FIG. 1 .
- ELISA testing with purified recombinant allergens showed that 60% percent of the patients were co-sensitized to rPhl p 1 and rPhl p 5, 30% contained IgE antibodies to rPhl p 2 and rPhl p 6 and 30% reacted simultaneously to all four recombinant allergens ( FIG. 1 ).
- Sera of 110 allergic patients were characterized by a positive timothy grass pollen RAST (radioallergosorbent test) result and by determination of IgE antibodies to timothy grass pollen extract by Western blotting as described (Niederberger et al. (1998) J Allergy Clin Immunol 101: 258-264).
- the recombinant timothy grass pollen allergens rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6 were purified as described previously (Vrtala et al. (1995) J. Allergy Clin. Immunol 97: 781-787; Vrtala et al. (1999) J. Immunol.
- the rabbit anti-rPhl p 1, anti-rPhl p 2, anti-rPhl p 5, and anti-rPhl p 6 antisera were raised against purified rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6 using CFA (Charles River, Kissleg, Germany).
- FIG. 2 The protocol for the construction of recombinant hybrid allergens is displayed in FIG. 2 .
- cDNAs coding for the components are amplified with suitable primer pairs ( FIG. 2 : Phl p 5: w, x; Phl p 1: y, z) in order to create overlapping ends.
- a cDNA comprising both cDNAs is created with primers specific for the 5′ end of the first cDNA (Phl p 5: w) and the 3′ end of the second cDNA (Phl p 1: z) using both PCR products of the first reactions as templates.
- the cDNAs of Phl p 5 and Phl p 1 were obtained by polymerase chain reaction using the primers 5′GGA ATT CAT ATG GCC GAT CTC GGT TAC 3′ (SEQ ID NO: 1) and 5′ CGG GGT ACC GAC TTT GTA GCC ACC AGT 3′ (SEQ ID NO: 2) for Phl p 5 and 5′ CGG GGT ACC ATG ATC CCC AAG GTT CCC 3′ (SEQ ID NO: 3) and 5′ CGG GAT CCT CAG TGG TGG TGG TGG TGG TGC TTG GAC TCG TAG CTG GT 3′ (SEQ ID NO: 4) for Phl p 1.
- the signal peptide of Phl p 5 was replaced by a Ndel restriction site, containing the ATG start codon at the 5′ end of the coding region.
- a Kpnl restriction site was introduced at the 3′ end of Phl p 5 replacing the stop-codon.
- the Phl p 1 sequence, lacking the signal peptide, started with a Kpnl restriction site at the 5′ end.
- a nucleotide strect coding for a Hexahistidine-tag was introduced, followed by a stop codon and a BamHI restriction site.
- the PCR products were inserted as Ndel/Kpnl/BamHI fragment into a pET17b expression vector.
- Phl p 2/Phl p 6 and Phl p 6/Phl p 2 sequences were constructed using PCR based ‘gene soeing’ (17).
- the cDNAs of Phl p 2 and Phl p 6 were amplified using the primers 5′ GGA ATT CAT ATG GTG CCG AAG GTG ACG 3′ (SEQ ID NO: 5), and 5′ CGT GGC CTT CCC CAT AAG CTT CTC TTC TGG CGC GTA GGT 3′ (SEQ ID NO: 6) for Phl p 2 and 5′ AAG CTT ATG GGG AAG GCC ACG ACC 3′ (SEQ ID NO: 7) and 5′ C GGG ATC CTA GTG GTG GTG GTG GTG GTG CGC GCC GGG CTT GAC AGC 3′ (SEQ ID NO: 8) for Phl p 6 to create overlapping ends.
- Phl p 6 sequence also lacking the signal peptide, a Hexahistidine tag was introduced followed by a stop codon and a BamHI restriction site.
- the resulting Phl p 2/Phl p 6 construct was inserted as a Ndel/BamHI fragment into the pET17b expression vector.
- the Phl p 6/Phl p 2 sequence was constructed using the same method with the PCR primers 5′ GGA ATT CAT ATG GGG AAG GCC ACG ACC GAG 3′ (SEQ ID NO: 11) and 5′ CAC CTT CGG CAC CAT AAG CTT CGC GCC GGG CTT GAC AGC 3′ (SEQ ID NO: 12) for Phl p 6 and 5′ AAG CTT ATG GTG CCG AAG GTG ACG 3′ (SEQ ID NO: 13) and 5′ C GGG ATC CTA GTG GTG GTG GTG GTG GTG CTC TTC TGG CGC GTA GGT 3′ (SEQ ID NO: 14) for Phl p 2 in the first PCR reaction and the primers 5′ GGA ATT CAT ATG GGG AAG GCC ACG ACC GAG 3′ (SEQ ID NO: 15) and 5′ C GGG ATC CTA GTG GTG GTG GTG GTG CTC TTC TGG CGC GGG
- the Phl p 6/Phl p 2/Phl p 5/Phl p 1 hybrid (“giant”) the Phl p 6/Phl p 2 construct was taken as a template in a PCR reaction using the primers 5′ GGA ATT CAT ATG GGG AAG GCC ACG ACC GAG 3′ (SEQ ID NO: 17) and 5′ GGG ATT TCC ATA TGC TCT TCT GGC GCG TAG G 3′ (SEQ ID NO: 18) replacing the 3′Hexahistidine tag and the stop codon by an Ndel restriction site. The sequence was cloned into the pET17b vector, containing the Phl p 5/Phl p 1 construct as a Ndel fragment. The right orientation of the insert was examined by restriction digest.
- FIG. 3 shows a Coomassie-stained SDS-PAGE containing three of the hybrids and the single recombinant allergens.
- the molecular mass determined by SDS-PAGE corresponded to the molecular weight calculated for the hybrids on the basis of their deduced amino acid sequence (rPhl p 5/rPhl p 1:60 kDa; rPhl p 2/rPhl p 6 and rPhl p 6/rPhl p 2:22 kDa; “giant”: 82 kDa; data not shown).
- rPhl p 2/rPhl p 6 and rPhl p 6/rPhl p 2 were expressed as soluble proteins.
- Cells were resuspended in lysis buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole, pH 8.0) and lysed with an ultraturrax (Polytron, Kinematica AG, Switzerland). The lysate was centrifuged at 10,000 ⁇ g for 30 min at 4° C. to pellet the cellular debris. The supernatant was loaded on a Ni-NTA column (QIAGEN), the proteins were eluted with 250 mM imidazole and dialyzed against water.
- lysis buffer 50 mM NaH 2 PO 4 , 300 mM NaCl, 10 mM imidazole, pH 8.0
- ultraturrax Polytron, Kinematica AG, Switzerland
- rPhl p 5/rPhl p 1 and rPhl p 6/rPhl p 2/rPhl p 5/rPhl p 1 were expressed in the inclusion body fraction.
- Cells were resuspended in 10 mM Tris, 0.1% Triton, pH 7.4 and lysed by adding lysozyme to 1 mg/ml. After centrifugation at 14 000 xg for 20 min at 4° C. the pellet was washed 4 ⁇ with 5 mM Tris pH 8.0, 0.05M NaCl, 0.25% Desoxicholate, 0.25 mM ⁇ -Mercaptoethanol and once with 10 mM Tris, pH 8.0, 3% isopropanole.
- Inclusion bodies were solubilized with 8M urea, 100 mM NaH 2 PO 4 , 10 mM Tris, pH 8.0. After centrifugation at 14 000 xg for 20 min the supernatant was loaded on a Ni-NTA column (Qiagen). The proteins were renatured on the column using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris, pH 7.4) over a period of 1.5 h (18). Proteins were eluted by addition of 250 mM imidazole and dialyzed against PBS pH 7.4.
- Recombinant hybrid allergens contained the complete primary amino acid sequences of their components and thus the complete repertoire of T cell epitopes of the single allergens.
- the presence of B cell epitopes was investigated with antibodies of predefined specificity for the individual components and by immunological competition experiments.
- FIG. 4 shows that the “giant” is recognized by antisera raised against rPhl p 1, rPhl p 2, rPhl p 5 and rPhl p 6, respectively ( FIG. 4 , row A: 1-4).
- the correct expression of the C-terminal hexahistidine tag was demonstrated by the reactivity of a mouse monoclonal anti-Histag antibody which specifically recognized the “Giant ( FIG.
- Table 1 shows that the rPhl p 2/rPhl p 6 as well as the rPhl p 6/rPhl p 2 hybrid inhibited IgE binding to both of the components (rPhl p 2, rPhl p 6) in a comparable manner as the single recombinant allergens (approximately 80% inhibition of IgE binding).
- Filters were blocked with TBS, 1% BSA, 0.05% Tween-20 for 1 hour and incubated with rabbit anti-Phl p 1, anti-Phl p 5 (diluted 1:5000), anti-Phl p 2 (diluted 1:500), anti-Phl p 6 (diluted 1:2000) sera, and a mouse monoclonal anti-Hexahistidin Ab (Dianova, Germany) diluted 1:1000 in TBS, 1% BSA, 0.05% Tween-20.
- Filters were washed 3 ⁇ with TBS, 0.05% Tween-20, incubated with a secondary alkaline phosphatase-coupled goat anti-rabbit IgG antibody (Jackson) and for the His-tag detection with a alkaline phosphatase-coupled anti-mouse IgG antibody (PharMingen) diluted 1:1000 in TBS, 1% BSA, 0.05% Tween-20 for 1 hour, and washed 3 ⁇ with TBS, 0.05% Tween-20. Colour reaction was started by adding NBT/BCIP (300 ⁇ g/ml) and stopped by the addition of water.
- NBT/BCIP 300 ⁇ g/ml
- FIG. 5 demonstrates that the average IgG 1 responses induced by the hybrid molecules to each of the individual allergens (rPhl p 1, rPhl p 2, rPhl p 5, or rPhl p 6) were higher than those obtained by immunization with the single allergen components.
- High IgG 1 antibody levels induced by the hybrids were already detectable 4 weeks after the first immunization and had increased further after 4 more weeks.
- mice Groups of 8 female BALB/c mice (age: 8 weeks) (Charles River, Germany) were immunized subcutaneously with rPhl p 1, rPhl p 2, rPhl p 5, rPhl p 6, rP2-P6, rP6-P2, rP5-P1, the giant molecule, timothy grass pollen extract, or an equimolar mixture of rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6 adsorbed to Al(OH) 3 (Alu-Gel-S, Serva, Ingelheim, Germany).
- mice were maintained in the animal care unit of the Institute of Pathophysiology, University of Vienna, according to the local guidelines for animal care. Mice were immunized and bled from the tail veins in four-week intervals and sera were stored at ⁇ 20° C. until analysis.
- Bound antibodies were detected with a 1:1000 diluted monoclonal rat anti-mouse IgG 1 (Pharmingen, San Diego, Calif., USA) and a 1:2000 diluted HRP-labeled sheep anti-rat antiserum (Amersham, Buckinghamshire, UK).
- Hybrid Molecules Induce Protective Antibody Responses that Block the Binding of Allergic Patients' IgE to Grass Pollen Allergens
- mice anti-rP2-P6, anti-rP6-P2, and anti-rP5-P1 antibodies were examined by ELISA competition experiments.
- Phl p 1, Phl p 2, Phl p 5, and Phl p 6 (1 ⁇ g/ml) were coated to ELISA plates (Nunc) over night at 4° C., plates were washed twice with TBST (Tris-buffered saline, 0.05% Tween), saturated with 200 ⁇ l TBST/1% BSA, and preincubated with mouse anti-rP2-P6, anti-rP6-P2, and anti-rP5-P1 antisera or, for control purposes, with the corresponding preimmune sera each diluted 1:50 in TBST/0.5% BSA over night at 4° C.
- TBST Tris-buffered saline, 0.05% Tween
- % inhibition of IgE binding 100 ⁇ OD l /OD p ⁇ 100.
- OD l and OD P represent the extinctions after preincubation with the immune serum and the preimmune serum, respectively.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Hybrid polypeptides comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein are disclosed. The hybrid polypeptides and polynucleotides coding therefor can be used as pharmaceutical compositions, in particular as vaccines.
Description
- Type I allergy is a genetically determined hypersensitivity disease affecting almost 500 million individuals worldwide. Immediate symptoms (allergic rhinoconjunctivitis, asthma, anaphylactic shock) as well as late symptoms (atopic dermatitis, certain forms of allergic asthma bronchiale) are based on the recognition of allergens by IgE antibodies. Immediate symptoms result from the allergen-induced crosslinking of effector cell-bound IgE and the subsequent release of biological mediators (e.g., histamine, leukotrienes) whereas late symptoms can be caused by IgE-mediated presentation of allergens to T cells and eosinophil activation.
- The only curative therapy approach, allergen-specific immunotherapy, is based on the systemic administration of allergens to patients in order to induce allergen-specific “unresponsiveness” (Noon, Lancet 1911, 1: 1572-1573; Bousquet et al. (1998) J Allergy Clin Immunol 102: 558-562; Durham and Till (1998) J. Allergy Clin. Immunol. 102, 157-164). Using conventional technologies it has not been possible to produce pure allergens for specific immunotherapy and hence, vaccination is performed with allergen extracts. These extracts consist of allergens and non-allergenic components which are difficult to standardize. Therefore patients cannot be treated according to their specific sensitization profile and anaphylactic side effects, due to the administration of allergenic material are frequently observed (Mellerup et al. (2000). Clin. Exp.
Allergy 30, 1423-1429). It is an objective of the present invention to provide an advantageous composition for the treatment or prevention of allergic disorders. - Surprisingly the inventors found that it is possible to generate hybrid allergens assembling the epitopes of immunologically distinct allergens for diagnosis and therapy of Type I allergy. The invention therefore relates to a hybrid polypeptide comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein.
- In the broadest scope of the present invention any polypeptide may be used in the hybrid polypeptide which may be involved in vaccination. The polypeptide may be derived from viruses such as HI, HC-viruses, bacteria, tumor antigens or plant allergens.
- The allergenic proteins from which the hybrid polypeptide is derived may preferably be a plant allergen. The different allergenic proteins may be derived from a common source such as the pollens of a certain plant species. Several different allergenic proteins contained in the allergen source may be identified and used for the preparation of the hybrid polypeptide of the invention. The present invention, however, encompasses also a hybrid polypeptide comprising sequences derived from allergenic proteins from different sources. The term “allergenic proteins or fragments thereof” comprises also modifications of the allergens wherein the sequence of the naturally occurring allergen has been slightly modified by substitutions of single amino acids or nucleotides whereby the allergenic potential has been substantially maintained.
- Allergen sources from which the allergenic proteins are derived may be major grass pollen, mite, bee venom or animal hair dander allergens. Specific examples of allergenic proteins are the
group 1,group 2,group 4,group 5group 6,group 11, group 12 and group 13 allergens of major grass pollen, Derp 1 and Der p 2 (mite), phospholipase from bee venom and Fel d 1 (cat). - In one embodiment the hybrid polypeptide comprises at least one complete allergenic protein. It may also comprise two different complete allergenic proteins. It is not only possible to combine different groups of allergenic grass pollen but also to combine allergenic proteins derived from different sources. In a particular embodiment all sequences of the hybrid polypeptide derived from allergenic proteins represent complete allergenic proteins.
- In another embodiment the hybrid polypeptide comprises at least one fragment of an allergenic protein wherein the fragment consists of at least eight consecutive amino acids of the respective allergenic protein. Preferably the fragment consists of at least 12, more preferably of at least 20 and most preferably of at least 30 consecutive amino acids of the respective allergenic proteins. In another embodiment all amino acid sequences derived from allergenic proteins are fragments of at least eight consecutive amino acids of the respective allergenic proteins from which they are derived. The preferred length of these fragments is at least 12, more preferably at least 20, most preferably at least 30 consecutive amino acids of the respective allergenic protein.
- When fragments of allergenic proteins are employed it is possible to prepare a hybrid polypeptide comprising only fragments which have an allergenic activity which is lower compared with the respective allergenic proteins from which they are derived. This effect may be due to the destruction of epitopes by modified secondary or tertiary structure of the fragment compared with the full length protein. In the most preferred embodiment, the hybrid polypeptide has an allergic activity which is lower than the allergenic activity of each of the allergenic proteins from which the hybrid polypeptide is derived. Usually, the allergenic activity of the hybrid polypeptide is less than 50% of that of each of the allergenic proteins from which the hybrid polypeptide is derived. In a particular embodiment, the hybrid polypeptide has substantially no allergenic activity.
- According to the invention the allergenic activity of a sample is determined by determining the IgE antibodies which are induced in a test animal upon application of the sample. The allergenic activity is preferably defined in suitable in vitro or in vivo tests. A preferred in vitro test is the basophil histamine release assay as described in Vrtala et al., J. Clin. Invest. 1997, 99, pp. 1673-1681. Alternatively the allergenic activity is determined in a skin test as described in van Hage-Hamsten et al. J. Allergy Clin. Immunol. 1999, 104, pp. 969-977 or in Pauli et al. Clin. Exp.
Allergy 2000, 30, pp. 1076-1084. - In one embodiment the hybrid polypeptide comprises two portions which are derived from two different allergenic proteins. The hybrid polypeptide of the invention, however, may comprise three, four, five or even more portions each of which is derived from a different allergenic protein.
- The hybrid polypeptide of the invention does not necessarily consist only of amino acid sequences derived from allergenic proteins. It is possible that artificial sequences (e.g. spacer sequences) are inserted between the units representing sequences from different allergenic proteins. It is also possible that the amino acid sequences of the naturally occurring allergenic proteins are modified, e.g. by genetic engineering to introduce mutations which reduce the allergenic activity of the fragment. It is also preferred that the hybrid polypeptide comprises a “tag” sequence which facilitates the purification of the hybrid polypeptide upon expression in a host cell. An example of a “tag” is the hexahistidine tag which allows purification by Ni2+ chelate chromatography. Other tags are known in the art.
- The hybrid polypeptide of the invention may be prepared by several methods. In one embodiment the polypeptide is prepared by expressing a polynucleotide in a host cell. The host cell may be a procaryotic or a eucaryotic cell. If procaryotic cells are used the host is preferably E. coli. Examples of eucaryotic cells are yeast, insect cells or cell lines like CHO cells. After introducing a suitable polynucleotide encoding the polypeptide of the invention into a host cell the host cell is cultured under conditions such that the polypeptide is expressed in the cell. The polypeptide may be secreted by the cell or accumulate inside the cell. Known purification methods can be used to recover the hybrid polypeptide from the cell or from the culture medium.
- The invention also encompasses the preparation of the hybrid polypeptide by chemical synthesis such as solid phase synthesis.
- The invention further concerns a polynucleotide encoding a hybrid polypeptide according to the invention. Due to the degeneracy of the genetic code many different polynucleotide molecules may encode a single polypeptide. The polynucleotide of the invention preferably is an expression construct for obtaining the polypeptide after expression in host cells. The expression construct may further comprise components which are generally known in the art such as promoter sequences, genes encoding resistance factors against antibiotics, a replication origin etc.
- The invention further relates to a cell transfected or transformed with a polynucleotide of the invention. The cell may be a eucaryotic cell or a procaryotic cell. Eucaryotic cells may be transfected by a method known per se such as calcium phosphate mediated transfection, electroporation, lipofection etc.
- The invention further relates to a pharmaceutical composition containing a polypeptide, polynucleotide or a cell according to the invention. The pharmaceutical composition may further contain a pharmaceutically acceptable carrier or diluent such as a buffer or salt solution. Preferably the pharmaceutical composition of the invention is a vaccine composition. In a particular embodiment the pharmaceutical composition further contains an adjuvant such as Al(OH)3.
- The invention also relates to a method for the preparation of a hybrid polypeptide of the invention. The method comprises providing a polynucleotide encoding a hybrid polypeptide, introducing said polynucleotide into a host cell, culturing the host cell thus obtained under conditions such that the hybrid polypeptide is expressed, and recovering the expression product from the cell. The polynucleotide may be prepared by methods known in the art, it is preferred that PCR technology is used to prepare the polynucleotide encoding the hybrid polypeptide.
- The invention further concerns the use of a hybrid polypeptide, of a polynucleotide or of a cell of the invention for the preparation of a medicament for the treatment of an allergic disorder.
- Such a medicament may be composed of the polynucleotide encoding a hybride vaccine which can be used directly for DNA-based vaccination against Type I allergy. The recombinant or synthetic hybrid polypeptide may be used to prepare formulations for the oral, sublingual or parenteral treatment of Type I allergic disorders as they are now routinely used for immunotherapy. Examples are formulations for sublingual immunotherapy or adjuvant bound hybrid polypeptides for injection immunotherapy. Possible applications comprise also cell based forms of immunotherapy which may be based on e.g., dendritic cells or other antigen presenting cells. Those cells are transformed and express the antigen in vivo. Preferably autologous cells transformed with suitable vectors are used.
- One mode of applications may be the subcutaneous injection of adjuvant-bound hybrid polypeptides. Another possibility is the oral or nasal administration of the hybrid polypeptide in order to induce immunological tolerance or anergy against the components of the hybrid polypeptides. All these possible formulations can be prepared according to rules (dosage, adjuvants, schemes of administration) which are known to the person skilled in the art.
- The invention also relates to the use of a hybrid polypeptide, of a polynucleotide, or of a cell of the invention for the preparation of a medicament for prophylactic vaccination or tolerance induction. Prophylactic administration of hybride polypeptides means the administration of the polypeptide to individuals, preferentially children, who do not yet suffer from Type I allergy in order to induce a state of immunological tolerance, anergy or non-responsiveness, or a protective immunity against the components of the hybrid vaccine. This may be achieved by the various protocols outlined for treatment of an established allergic disorder. The prophylactic treatment may be performed with hybrid polypeptides consisting of hybride polypeptides or the polynucleotides coding for the hybrid polypeptides as outlined before.
- In a further embodiment the invention relates to the use of a hybrid polypeptide of the invention for the detection of antibodies against an allergenic protein in a sample. The antibody may be an IgM, IgE, IgG or IgA antibody. The concentration of the antibody may be determined from a sample which has been obtained from a body fluid. The sample may be derived from animals or humans. Such tests may use a solid phase-immobilized hybrid polypeptide or the hybrid polypeptide in the fluid phase. Examples for such tests may be ELISA tests. Westernblotting tests or any other test where the hybrid polypeptide is immobilized to bind specific antibodies out from the test sample. Alternatively the hybrid polypeptide is added directly to the antibody-containing fluid in order to adsorb specific antibodies as e.g., is done for competitive immunological assays.
- The polypeptide of the invention may also be used for cellular tests such as a T-cell proliferation test, mediator release test etc. The hybridpolypeptide may be exposed to various types of cells in order to elicit measurable responses. Such responses may comprise the release of histamine or other mediators (e.g., leukotriens, serotonine, ECP) in the case of allergic effector cells (e.g., basophils mast cells, eosinophils). In another type of assay the proliferation or death (e.g., apoptosis) of cells may be measured e.g., by the uptake of 3H Thymidine or any other suitable assay. Such cells may be T cells. Furthermore, hybrid polypeptides may be used to induce the release of cytokines or other immunologically relevant substances (e.g., from T cells) that can be measured. Furthermore, they may be used for antigen presentation assays. The hybrid polypeptide of the invention may also be used for diagnostic screening purposes. Hybrid polypeptides may be also used for in vivo provocation testing. Such tests may comprise skin testing (e.g., skin prick or intradermal testing), nasal provocation testing, all forms of food challenge testing or bronchial provocation testing.
- Since hybrid polypeptides can contain epitopes of unrelated allergens they may be used for diagnostic screening tests (in vitro, in vivo as outlined above) in order to detect sensitization or unresponsiveness against one of the components of the hybrid polypeptide. This may allow to provide the physician with a diagnostic test which is suited to screen for sensitized patients in a fast way. Currently such tests (e.g., Phadiatop, Pharmacia, Uppsala, Sweden) consist of a mixture of non-covalently bound allergens which are coupled to one carrier. Therefore, the coupling rate of the individual components is difficult to control whereas a hybrid polypeptide would represent a preferential formulation for the preparation of such a screening test.
- More than 40% of allergic patients are sensitized to grass pollens from different species. Grasses are also important allergen sources because of their worldwide distribution and heavy pollen production. They contain a variety of different allergenic components which occur as crossreactive allergens in different monocots. The inventors demonstrated that it is possible to generate by recombinant DNA technology hybrid allergens which consist of immunologically unrelated allergens and their epitopes.
- In a first step frequent co-sensitizations were determined using purified recombinant timothy grass pollen allergens to select the most frequently recognized allergen combinations for the hybrid allergen approach. According to the pilot experiments hybrids consisting of immunologically unrelated major timothy grass pollen allergens were engineered. They comprised hybrids of the major timothy grass pollen
allergens Phl p 5/Phl p 1,Phl p 2/Phl p 6 and a combination of all four molecules. As demonstrated forPhl p 2/Phl p 6 we found no evidence that a certain order of engineering the individual components would affect the presentation of epitopes. Both, therPhl p 2/Phl p 6 hybrid and therPhl p 6/Phl p 2 hybrid preserved the relevant B and T cell epitopes of the components. The giant consisting of all 4 allergens also contained the relevant epitopes of the single components. - The hybrid allergen approach will open new avenues for diagnosis and treatment of Type I allergy. Hybrids consisting of the most frequently recognized allergens with preserved epitopes represent candidate molecules for in vitro as well as in vivo allergy screening tests. The giant described in the present application will likely identify more than 95% of timothy grass pollen allergic patients when used for diagnosis, because it resembles most of the relevant IgE epitopes present in natural timothy grass pollen extract. Molecules such as the giant can be produced also for other allergen systems (e.g., mite allergy). The advantage of using hybrid allergens for diagnosis is that they can be produced in a well controlled manner. In contrast to natural allergen extracts, which consist of a difficult to standardize mixture of allergens and non-allergenic materials, hybrid allergens will contain the relevant epitopes in a well defined ratio.
- Recombinant hybrid allergens can also be used for immunotherapy. They can either be composed of the biologically active components or of hypoallergenic allergen units. Hybrid allergens covering frequent co-sensitization patterns may then be used for the treatment of allergies to complex allergen sources, e.g., grass pollen allergy because they resemble the relevant epitopes of the complete extract. Since the hybrid allergens consist of defined components it will be possible to produce well defined formulations for vaccination treatment. Hybrid allergens produced out of hypoallergenic variants will be tolerated in high doses and thus can be used like vaccines regularly used for prevention of viral infections. In this respect it may be considered to use hybrid allergens containing the epitopes of the most relevant allergens for prophylactic vaccination or tolerance induction even in not yet sensitized individuals.
- The fact that the fusion of different antigenic components in form of a hybrid molecule increased the immunogenicity of the individual components has several implications for allergen-specific immunotherapy and for vaccination in general. Allergens or antigens against which immune responses are desired and which per se exhibit low immunogenicity can be fused to hybrids to increase their immunogenicity without using other carrier proteins or adjuvants. This principle will allow to induce high levels of protective antibody responses against allergens, allergen fragments, allergen epitopes or mimics thereof. Using this principle it is also possible to increase the immune response towards antigens/epitopes derived from infectious agents, tumors or other components against which it is difficult to induce immune responses.
- Table 1 shows the percentage inhibition of IgE binding to
recombinant Phl p 2 andPhl p 6 achieved after preadsorption of sera from 20 patients with the hybrid allergens (rPhl p 2/rPhl p 6,rPhl p 6/rPhl p 2) or the recombinant allergens (rPhl p 2, rPhl p 6). - Table 2 shows the percentage inhibition of IgE binding to
recombinant Phl p 1,Phl p 5, andBet v 1 achieved after preadsorption of sera from 20 patients with the hybridallergen rPhl p 5/rPhl p 1 or the recombinant allergens (rPhl p 1,rPhl p 5, and rBet v 1). - Table 3. Mouse antisera raised against hybrid molecules inhibit the binding of grass pollen allergic patients IgE to the individual allergens. ELISA plate-bound allergens (A:
rPhl p 2 andrPhl p 6; B:rPhl p 1 and rPhl p 5) were preincubated with mouse antisera (mouse anti-rP2-P6, anti-rP6-P2,anti-rPhl p 2,anti-rPhl p 6, anti-rP5-P1,anti-rPhl p 1,anti-rPhl p 5. The percentages inhibition of IgE binding obtained for 4 grass pollen allergic patients are displayed. -
FIG. 1 shows the frequency of co-sensitization to timothy grass pollenallergens rPhl p 1,rPhl p 2,rPhl p 5, andrPhl p 6 as determined in a population of 110 grass pollen allergic patients. -
FIG. 2 outlines the construction of hybrid vaccines. The fusion of the two genes (e.g. Phl p 5, Phl p 1) is mediated by a two-step PCR reaction, creating overlapping ends in the first PCR reaction followed by the amplification of both sequences in a second PCR step. -
FIG. 3 shows the result of example 3. Purified timothy grass pollen allergens (rPhl p 1,rPhl p 2,rPhl p 5, and rPhl p 6) and hybrids of them (rPhl p 5/rPhl p 1,rPhl p 2/rPhl p 6, andrPhl p 6/rPhl p 2) were loaded on a SDS polyacrylamide gel and stained with Coomassie brilliant blue. Molecular weights are displayed at the left margin. - In
FIG. 4 (A) a purified recombinant hybrid consisting ofPhl p 6/Phl p 2/Phl p 5/Phl p 1 was dotted on nitrocellulose filters. In row (B) rPhl p 2 (lane lane 5 was exposed to a mouse monoclonal anti-His-tag antibody. -
FIGS. 5 to 7 show that recombinant hybrid molecules induce stronger IgG1 antibody responses in mice than the individual components or mixtures thereof. -
FIG. 5 . ELISA plate-bound purified recombinant allergens (A:rPhl p 2; B:rPhl p 6; C:rPhl p 1; D: rPhl p 5) were incubated with sera from mice (8 mice per group) which had been immunized with the hybrid molecules (rP2-P6, rP6-P2, rP5-P1), the individual recombinant allergens (rPhl p 1,rPhl p 2,rPhl p 5, rPhl p 6), or with timothy grass pollen extract as indicated on the x-axis. Mean IgG1 levels of sera collected 4 and 8 weeks after immunization correspond to the OD values displayed on the y-axis. -
FIG. 6 . ELISA plate-bound purified recombinant allergens (rPhl p 1,rPhl p 2,rPhl p 5, rPhl p 6) were incubated with sera from mice (8 mice per group) which had been immunized with (A) the giant molecule or the individual recombinantallergens rPhl p 1,rPhl p 2,rPhl p 5,rPhl p 6, and with (B) the giant molecule or an equimolar mixture ofrPhl p 1,rPhl p 2,rPhl p 5, andrPhl p 6 as indicated on the x-axis. Mean IgG1 levels of sera collected 4 and 8 weeks after immunization correspond to the OD values displayed on the y-axis. -
FIG. 7 . The ELISA plate-bound giant (A), and timothy grass pollen extract (B) were incubated with sera from mice (8 mice per group) which had been immunized with the giant or timothy grass pollen extract as indicated on the x-axis. Mean IgG1 levels of sera collected 4 and 8 weeks after immunization correspond to the OD values displayed on the y-axis. - The following examples further illustrate the invention:
- Grasspollen contain a variety of immunologically distinct and related allergens. These components are recognized at different frequencies and intensities. Recombinant timothy grass pollen allergens,
rPhl p 1,rPhl p 2,rPhl p 5, andrPhl p 6, were previously identified as the most important components which resemble most of the IgE epitopes of natural grass pollen extracts (Niederberger et al. (1998) IgE antibodies to recombinant pollen allergens (Phl p 1,Phl p 2,Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J Allergy Clin Immunol 101: 258-264). The results of the evaluation of co-sensitizations in 110 grass pollen allergic patients to combinations of the recombinant timothy grass pollen allergens are displayed inFIG. 1 . ELISA testing with purified recombinant allergens showed that 60% percent of the patients were co-sensitized torPhl p 1 andrPhl p rPhl p 2 andrPhl p FIG. 1 ). Previous competition studies had indicated that a mixture of the above four allergens contained the majority of IgE epitopes present in 8 different monocot pollens (grasses, corn) (Laffer et al. (1996) Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations. J Allergy Clin Immunol; 98: 652-658). - Patients Sera, Antisera and Recombinant Allergens:
- Sera of 110 allergic patients were characterized by a positive timothy grass pollen RAST (radioallergosorbent test) result and by determination of IgE antibodies to timothy grass pollen extract by Western blotting as described (Niederberger et al. (1998) J Allergy Clin Immunol 101: 258-264). The recombinant timothy grass pollen
allergens rPhl p 1,rPhl p 2,rPhl p 5, andrPhl p 6 were purified as described previously (Vrtala et al. (1995) J. Allergy Clin. Immunol 97: 781-787; Vrtala et al. (1999) J. Immunol. 163:5489-5496). Therabbit anti-rPhl p 1,anti-rPhl p 2,anti-rPhl p 5, andanti-rPhl p 6 antisera were raised against purifiedrPhl p 1,rPhl p 2,rPhl p 5, andrPhl p 6 using CFA (Charles River, Kissleg, Germany). - The protocol for the construction of recombinant hybrid allergens is displayed in
FIG. 2 . As exemplified for a hybrid consisting ofrPhl p 5 linked torPhl p 1, cDNAs coding for the components are amplified with suitable primer pairs (FIG. 2 : Phl p 5: w, x; Phl p 1: y, z) in order to create overlapping ends. In a subsequent second PCR reaction, a cDNA comprising both cDNAs is created with primers specific for the 5′ end of the first cDNA (Phl p 5: w) and the 3′ end of the second cDNA (Phl p 1: z) using both PCR products of the first reactions as templates. Using this technology we produced recombinant hybrids consisting of a combination ofPhl p 5/Phl p 1,rPhl p 2/rPhl p 6,rPhl p 6/rPhl p 2 and of all four allergens (N-terminus-rPhl p 6-rPhl p 2-rPhl p 5-rPhl p 1-C-terminus), the latter referred to as the “giant”. - Construction of expression plasmids for
rPhl p 5/rPhl p 1-,rPhl p 2/rPhl p 6-,rPhl p 6/rPhl p 2-, andrPhl p 6/rPhl p 2/rPhl p 5/rPhl p 1 hybrid proteins: - The cDNAs of
Phl p 5 andPhl p 1 were obtained by polymerase chain reaction using theprimers 5′GGA ATT CAT ATG GCC GATCTC GGT TAC 3′ (SEQ ID NO: 1) and 5′ CGG GGT ACC GAC TTT GTAGCC ACC AGT 3′ (SEQ ID NO: 2) forPhl p AAG GTT CCC 3′ (SEQ ID NO: 3) and 5′ CGG GAT CCT CAG TGG TGG TGG TGG TGG TGC TTG GAC TCGTAG CTG GT 3′ (SEQ ID NO: 4) forPhl p 1. The signal peptide ofPhl p 5 was replaced by a Ndel restriction site, containing the ATG start codon at the 5′ end of the coding region. A Kpnl restriction site was introduced at the 3′ end ofPhl p 5 replacing the stop-codon. ThePhl p 1 sequence, lacking the signal peptide, started with a Kpnl restriction site at the 5′ end. At the 3′ end a nucleotide strect coding for a Hexahistidine-tag was introduced, followed by a stop codon and a BamHI restriction site. The PCR products were inserted as Ndel/Kpnl/BamHI fragment into a pET17b expression vector. - The
Phl p 2/Phl p 6 andPhl p 6/Phl p 2 sequences were constructed using PCR based ‘gene soeing’ (17). In a first PCR reaction the cDNAs ofPhl p 2 andPhl p 6 were amplified using theprimers 5′ GGA ATT CAT ATG GTG CCGAAG GTG ACG 3′ (SEQ ID NO: 5), and 5′ CGT GGC CTT CCC CAT AAG CTT CTC TTC TGGCGC GTA GGT 3′ (SEQ ID NO: 6) forPhl p GCC ACG ACC 3′ (SEQ ID NO: 7) and 5′ C GGG ATC CTA GTG GTG GTG GTG GTG GTG CGC GCC GGGCTT GAC AGC 3′ (SEQ ID NO: 8) forPhl p 6 to create overlapping ends. In a subsequent PCR reaction the two agarose gel purified PCR products (using QIAGEN gel purification kit) were used as templates and amplified using theprimers 5′ GGA ATT CAT ATG GTG CCGAAG GTG ACG 3′ (SEQ ID NO: 9) and 5′ C GGG ATC CTA GTG GTG GTG GTG GTG GTG CGC GCC GGG CTT GAC AGC (SEQ ID NO: 10). The signal peptide ofPhl p 2 was replaced by a Ndel restriction site at the 5′ end, the stop codon at the 3′ end was removed. In thePhl p 6 sequence, also lacking the signal peptide, a Hexahistidine tag was introduced followed by a stop codon and a BamHI restriction site. The resultingPhl p 2/Phl p 6 construct was inserted as a Ndel/BamHI fragment into the pET17b expression vector. - The
Phl p 6/Phl p 2 sequence was constructed using the same method with thePCR primers 5′ GGA ATT CAT ATG GGG AAG GCCACG ACC GAG 3′ (SEQ ID NO: 11) and 5′ CAC CTT CGG CAC CAT AAG CTT CGC GCC GGGCTT GAC AGC 3′ (SEQ ID NO: 12) forPhl p AAG GTG ACG 3′ (SEQ ID NO: 13) and 5′ C GGG ATC CTA GTG GTG GTG GTG GTG GTG CTC TTC TGGCGC GTA GGT 3′ (SEQ ID NO: 14) forPhl p 2 in the first PCR reaction and theprimers 5′ GGA ATT CAT ATG GGG AAG GCCACG ACC GAG 3′ (SEQ ID NO: 15) and 5′ C GGG ATC CTA GTG GTG GTG GTG GTG GTG CTC TTC TGGCGC GTA GGT 3′ (SEQ ID NO: 16) for the second PCR reaction. The resultingPhl p 6/Phl p 2 construct was inserted in the pET17b vector as a Ndel/BamHI fragment. - For the construction of the
Phl p 6/Phl p 2/Phl p 5/Phl p 1 hybrid (“giant”) thePhl p 6/Phl p 2 construct was taken as a template in a PCR reaction using theprimers 5′ GGA ATT CAT ATG GGG AAG GCCACG ACC GAG 3′ (SEQ ID NO: 17) and 5′ GGG ATT TCC ATA TGC TCT TCT GGCGCG TAG G 3′ (SEQ ID NO: 18) replacing the 3′Hexahistidine tag and the stop codon by an Ndel restriction site. The sequence was cloned into the pET17b vector, containing thePhl p 5/Phl p 1 construct as a Ndel fragment. The right orientation of the insert was examined by restriction digest. - Recombinant hybrid allergens with a C-terminal hexahistidine tag were expressed in E. coli BL21 (DE3) and purified by Nickel affinity chromatography. The
rPhl p 2/rPhl p 6 andrPhl p 6/rPhl p 2 hybrid were purified from the soluble cytoplasmic fraction of E. coli extracts whereas therPhl p 5/rPhl p 1 hybrid and the “giant” were solubilized from the insoluble inclusion body fraction of E. coli in urea.FIG. 3 shows a Coomassie-stained SDS-PAGE containing three of the hybrids and the single recombinant allergens. The molecular mass determined by SDS-PAGE corresponded to the molecular weight calculated for the hybrids on the basis of their deduced amino acid sequence (rPhl p 5/rPhl p 1:60 kDa;rPhl p 2/rPhl p 6 andrPhl p 6/rPhl p 2:22 kDa; “giant”: 82 kDa; data not shown). - All constructs were expressed in E. coli BL21 (DE3). Cells were grown in LB-medium containing 100 mg/l ampicillin to an OD600 of 0.8. The expression of the recombinant proteins was induced by adding isopropyl-β-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM. After 4 hours at 37° C. cells were harvested by centrifugation.
-
rPhl p 2/rPhl p 6 andrPhl p 6/rPhl p 2 were expressed as soluble proteins. Cells were resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) and lysed with an ultraturrax (Polytron, Kinematica AG, Switzerland). The lysate was centrifuged at 10,000×g for 30 min at 4° C. to pellet the cellular debris. The supernatant was loaded on a Ni-NTA column (QIAGEN), the proteins were eluted with 250 mM imidazole and dialyzed against water. -
rPhl p 5/rPhl p 1 andrPhl p 6/rPhl p 2/rPhl p 5/rPhl p 1 were expressed in the inclusion body fraction. Cells were resuspended in 10 mM Tris, 0.1% Triton, pH 7.4 and lysed by adding lysozyme to 1 mg/ml. After centrifugation at 14 000 xg for 20 min at 4° C. the pellet was washed 4× with 5 mM Tris pH 8.0, 0.05M NaCl, 0.25% Desoxicholate, 0.25 mM β-Mercaptoethanol and once with 10 mM Tris, pH 8.0, 3% isopropanole. Inclusion bodies were solubilized with 8M urea, 100 mM NaH2PO4, 10 mM Tris, pH 8.0. After centrifugation at 14 000 xg for 20 min the supernatant was loaded on a Ni-NTA column (Qiagen). The proteins were renatured on the column using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris, pH 7.4) over a period of 1.5 h (18). Proteins were eluted by addition of 250 mM imidazole and dialyzed against PBS pH 7.4. - Recombinant hybrid allergens contained the complete primary amino acid sequences of their components and thus the complete repertoire of T cell epitopes of the single allergens. The presence of B cell epitopes was investigated with antibodies of predefined specificity for the individual components and by immunological competition experiments.
FIG. 4 shows that the “giant” is recognized by antisera raised againstrPhl p 1,rPhl p 2,rPhl p 5 andrPhl p 6, respectively (FIG. 4 , row A: 1-4). The correct expression of the C-terminal hexahistidine tag was demonstrated by the reactivity of a mouse monoclonal anti-Histag antibody which specifically recognized the “Giant (FIG. 4 : row A, 5) but notrPhl p 2 containing no hexahistidine tag (FIG. 4 : row B, 5). Recombinant Phl p 2 (row B: 1, 3, 4) and rPhl p 5 (row B: 2) (negative controls) did not react with the antisera (FIG. 4 : row B). - Next we investigated whether the hybrid allergens can be used to block the binding of grass pollen allergic patients (n=20) IgE antibodies to the individual components (Tables 1, 2). Table 1 shows that the
rPhl p 2/rPhl p 6 as well as therPhl p 6/rPhl p 2 hybrid inhibited IgE binding to both of the components (rPhl p 2, rPhl p 6) in a comparable manner as the single recombinant allergens (approximately 80% inhibition of IgE binding). Likewise, we found that therPhl p 5/rPhl p 1 hybrid inhibited IgE binding of the 20 patients to both,rPhl p 1 andrPhl p 5, as efficient as the single components (average inhibition 85%) (Table 2). No inhibition was observed when sera were preabsorbed with therPhl p 5/rPhl p 1 hybrid and reacted with an unrelated allergen (major birch pollen allergen, Bet v 1) whereasrBet v 1 caused almost complete autoinhibition (83% inhibition) (Table 2). - Sera from 20 patients were diluted 1:10 in Tris-buffered saline (TBS) for the inhibition with
rPhl p 5/rPhl p 1 and 1:5 for inhibition withrPhl p 2/rPhl p 6 andrPhl p 6/rPhl p 2. The sera were preabsorbed overnight at 4° C. eitherrecombinant Phl p 1,Phl p 5,Phl p 5/Phl p 1,Phl p 2,Phl p 6,Phl p 2/Phl p 6,Phl p 6/Phl p 2,Bet v 1, or BSA (10 μg/ml). ELISA plates were coated withrecombinant Phl p 1,Phl p 2,Phl p 5,Phl p 6, and Bet v 1 (5 μg/ml) at 4° C. overnight. The ELISA was performed as described (Niederberger et al. (1998) J Allergy Clin Immunol 101: 258-264). - Aliquots of approximately 1 μg of purified,
recombinant Phl p 6/Phl p 2/Phl p 5/Phl p 1, andrPhl p 5 andrPhl p 2 as negative controls, were dotted on nitrocellulose membranes. Filters were blocked with TBS, 1% BSA, 0.05% Tween-20 for 1 hour and incubated withrabbit anti-Phl p 1, anti-Phl p 5 (diluted 1:5000), anti-Phl p 2 (diluted 1:500), anti-Phl p 6 (diluted 1:2000) sera, and a mouse monoclonal anti-Hexahistidin Ab (Dianova, Germany) diluted 1:1000 in TBS, 1% BSA, 0.05% Tween-20. Filters were washed 3× with TBS, 0.05% Tween-20, incubated with a secondary alkaline phosphatase-coupled goat anti-rabbit IgG antibody (Jackson) and for the His-tag detection with a alkaline phosphatase-coupled anti-mouse IgG antibody (PharMingen) diluted 1:1000 in TBS, 1% BSA, 0.05% Tween-20 for 1 hour, and washed 3× with TBS, 0.05% Tween-20. Colour reaction was started by adding NBT/BCIP (300 μg/ml) and stopped by the addition of water. - To evaluate weather immunization with the hybrid allergens induces IgG antibodies that recognize the individual allergen components, groups of 8 mice each were immunized with the hybrids, the individual allergens or timothy grass pollen extract.
FIG. 5 demonstrates that the average IgG1 responses induced by the hybrid molecules to each of the individual allergens (rPhl p 1,rPhl p 2,rPhl p 5, or rPhl p 6) were higher than those obtained by immunization with the single allergen components. High IgG1 antibody levels induced by the hybrids were already detectable 4 weeks after the first immunization and had increased further after 4 more weeks. Perhaps most interesting was the finding that the hybrid molecules induced higher IgG1 levels to the individual allergen components than timothy grass pollen extract (FIG. 5 ). The latter was particularly evident forPhi p 2,Phl p 6 andPhl p 1 which were poorly recognized by extract-induced antibodies, whereas the hybrid molecules induced vigorous anti-Phl p 1-, anti-Phl p 2- andanti-Phl p 6 antibody responses (FIG. 5 ). - Likewise we found that immunization with the giant molecule induced stronger antibody responses to each of the components (
Phl p 1,Phl p 2,Phl p 5, Phl p 6) than immunization with the individual antigens (FIG. 6A ) or an equimolar mixture of the antigens (FIG. 6B ). Immunization with the giant yielded also better immune responses than immunization with timothy grass pollen extract. IgG antibodies induced with timothy grass pollen extract exhibited lower reactivity to the giant and to the extract than those induced with the giant (FIG. 7A , B). - Groups of 8 female BALB/c mice (age: 8 weeks) (Charles River, Germany) were immunized subcutaneously with
rPhl p 1,rPhl p 2,rPhl p 5,rPhl p 6, rP2-P6, rP6-P2, rP5-P1, the giant molecule, timothy grass pollen extract, or an equimolar mixture ofrPhl p 1,rPhl p 2,rPhl p 5, andrPhl p 6 adsorbed to Al(OH)3 (Alu-Gel-S, Serva, Ingelheim, Germany). Animals were maintained in the animal care unit of the Institute of Pathophysiology, University of Vienna, according to the local guidelines for animal care. Mice were immunized and bled from the tail veins in four-week intervals and sera were stored at −20° C. until analysis. - IgG1 responses against
rPhl p 1,rPhl p 2,rPhl p 5,rPhl p 6, rP2-P6, rP6-P2, rP5-P1, the giant molecule, an equimolar mixture ofrPhl p 1,rPhl p 2,rPhl p 5, andrPhl p 6, and timothy grass pollen extract were measured by ELISA. Allergens (recombinant allergens: 5 μg/ml; extract: 50 μg/ml) were coated to Nunc Maxisorp plates (Roskilde, Denmark) and incubated with 1:1000 diluted mouse-sera. Bound antibodies were detected with a 1:1000 diluted monoclonal rat anti-mouse IgG1 (Pharmingen, San Diego, Calif., USA) and a 1:2000 diluted HRP-labeled sheep anti-rat antiserum (Amersham, Buckinghamshire, UK). - Next we examined whether mouse antibodies induced with the hybrid molecules can block the binding of grass pollen allergic patients IgE antibodies to purified grass pollen allergens (Table 3). ELISA competition experiments performed with sera from 4 representative grass pollen allergic patients showed that antibodies induced by the hybrid molecules strongly inhibited IgE binding to the purified allergens: IgG antibodies induced with the rP2-P6 and the rP6-P2 hybrid molecule caused a 48%-54% inhibition of IgE binding to
Phl p 2 and a 54%-67% inhibition of IgE binding to Phi p 6 (Table 3A). By contrast, the inhibition of IgE reactivity yielded by preincubation with antibodies induced withrPhl p 2 andrPhl p 6 alone was very low (0-15%) (Table 3A). Anti-P5-P1 antibodies caused a more than double inhibition of IgE binding to Phl p 5 (59.5% average inhibition) than antibodies raised againstPhl p 5 alone (28%) (Table 3B). The inhibition of IgE binding toPhl p 1 yielded with the antibodies raised against the rP5-P1 hybrid (18.5% average inhibition) andPhl p 1 alone (29.5% average inhibition) were lower (Table 3B). - Similar results were obtained with the giant molecule which induced IgG antibodies that efficiently blocked the binding of grass pollen allergic patients IgE to
Phl p 1,Phl p 2,Phl p 5,Phl p 6 and timothy grass pollen extract (data not shown). - The ability of the mouse anti-rP2-P6, anti-rP6-P2, and anti-rP5-P1 antibodies to inhibit the binding of grass pollen allergic patients' IgE Abs to
rPhl p 1,rPhl p 2,rPhl p 5, orrPhl p 6 was examined by ELISA competition experiments.Recombinant Phl p 1,Phl p 2,Phl p 5, and Phl p 6 (1 μg/ml) were coated to ELISA plates (Nunc) over night at 4° C., plates were washed twice with TBST (Tris-buffered saline, 0.05% Tween), saturated with 200 μl TBST/1% BSA, and preincubated with mouse anti-rP2-P6, anti-rP6-P2, and anti-rP5-P1 antisera or, for control purposes, with the corresponding preimmune sera each diluted 1:50 in TBST/0.5% BSA over night at 4° C. After washing 5 times with TBST, plates were incubated with human sera from grass pollen allergic patients diluted 1:5 in TBST/0.5% BSA over night at 4° C. After washing 5 times with TBST, bound human IgE was detected with an AP-labeled mouse anti-human IgE Ab (Pharmingen) diluted 1:1000 in TBST/0.5% BSA (1 hour at 37° C., 1 hour at 4° C.). After washing 5 times with TBST, the colour reaction was started by adding 100 μl ELISA substrate (Sigma Diagnostics, Inc., St. Louis, USA) The percentage of reduction of human IgE binding after preincubation with mouse antisera was determined according to the formula: % inhibition of IgE binding=100−ODl/ODp×100. ODl and ODP represent the extinctions after preincubation with the immune serum and the preimmune serum, respectively.
Claims (21)
1-6. (canceled)
7. A polynucleotide encoding a fusion allergens consisting of recombinant polypeptides of two or more different naturally occurring timothy grass pollen allergens for use as immunotherapeutic agents.
8. (canceled)
9. A cell transfected or transformed with the polynucleotide of claim 7 .
10-21. (canceled)
22. A method for treating an allergic disorder comprising administering a pharmaceutical composition of recombinant polypeptides of two or more different naturally occurring timothy grass pollen allergens to a patient in need thereof.
23. A method for inducing tolerance to a given allergen, comprising administering a pharmaceutical composition of recombinant polypeptides of two or more different naturally occurring timothy grass pollen allergens to a patient in need thereof.
24. A method for providing immunity to a given allergen, comprising administering a pharmaceutical composition of recombinant polypeptides of two or more different naturally occurring timothy grass pollen allergens to a patient in need thereof.
25. A method for detecting antibodies against a given allergenic protein in a sample, comprising conducting in vitro antibody tests employing the hybrid polypeptide of any one of claims 1 to 6 or conducting in vitro or in vivo cellular-based tests employing the hybrid polypeptide of any one of claims 1 to 6.
26-35. (canceled)
36. A method of identifying plant hybrid allergens for treatment of IgE-mediated hypersensitivity to the respective wild-type allergens comprising the steps of:
(a) providing a fusion allergen of naturally occurring plant allergens;
(b) challenging an immunological model with said fusion allergen;
(c) selecting as candidate immunotherapeutic agents, those fusion allergens which induce IgE-blocking antibodies and have reduced allergenic activity compared with the respective wild-type allergens.
37. The method of claim 36 , wherein the hybrid allergen is a fusion protein of two or more wild-type allergens.
38. The method of claim 36 , wherein the hybrid allergen is a fusion protein of fragments of two or more wild-type allergens.
39. The method of claim 36 , wherein the hybrid allergen is a fusion protein of fragments of two or more wild-type allergens, and wherein each fragment contains at least eight consecutive amino acids of the wild-type allergen.
40. The method of claim 37 , wherein the hybrid allergen is a fusion protein of one or more modifications of at least one of the two or more wild-type allergens.
41. The method of claim 36 , wherein the hybrid allergen is prepared by chemical synthesis.
42-43. (canceled)
44. A method of treating IgE-mediated hypersensitivity to plant allergens comprising administering to a patient in need of such treatment, a pharmaceutical composition comprising one or more hybrid plant fusion allergens as immunotherapeutic agents, wherein said agents have been identified by a method comprising the steps of:
(a) providing fusion allergens of naturally occurring plant allergens;
(b) challenging an immunological model with said fusion allergen;
(c) selecting as candidate immunotherapeutic agents, those fusion allergens which induce IgE-blocking antibodies and have reduced allergenic activity compared with the respective wild-type allergens.
45-47. (canceled)
48-51. (canceled)
52-53. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/954,821 US20110150920A1 (en) | 2000-12-28 | 2010-11-26 | Allergy Vaccines Containing Hybrid Polypeptides |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPEP00128660.8 | 2000-12-28 | ||
EP00128660A EP1221317A1 (en) | 2000-12-28 | 2000-12-28 | Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins |
US10/026,914 US7862828B2 (en) | 2000-12-28 | 2001-12-27 | Allergy vaccines containing hybrid polypeptides |
US12/954,821 US20110150920A1 (en) | 2000-12-28 | 2010-11-26 | Allergy Vaccines Containing Hybrid Polypeptides |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/026,914 Division US7862828B2 (en) | 2000-12-28 | 2001-12-27 | Allergy vaccines containing hybrid polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110150920A1 true US20110150920A1 (en) | 2011-06-23 |
Family
ID=8170854
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/026,914 Expired - Fee Related US7862828B2 (en) | 2000-12-28 | 2001-12-27 | Allergy vaccines containing hybrid polypeptides |
US12/954,821 Abandoned US20110150920A1 (en) | 2000-12-28 | 2010-11-26 | Allergy Vaccines Containing Hybrid Polypeptides |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/026,914 Expired - Fee Related US7862828B2 (en) | 2000-12-28 | 2001-12-27 | Allergy vaccines containing hybrid polypeptides |
Country Status (8)
Country | Link |
---|---|
US (2) | US7862828B2 (en) |
EP (2) | EP1221317A1 (en) |
AT (1) | ATE367826T1 (en) |
DE (1) | DE60129528T2 (en) |
DK (1) | DK1219301T3 (en) |
ES (1) | ES2287067T3 (en) |
HK (1) | HK1046648B (en) |
PT (1) | PT1219301E (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1440979B1 (en) * | 2003-01-21 | 2005-10-19 | BIOMAY Produktions- und Handels- Aktiengesellschaft | Process for the preparation of hypoallergenic mosaic proteins |
US8709435B2 (en) | 2003-01-21 | 2014-04-29 | Biomay Ag | Hypallergenic mosaic antigens and methods of making same |
ITRM20030247A1 (en) * | 2003-05-20 | 2004-11-21 | Bonura Angela | HYPOALLERGENIC VARIANTS OF MAJOR ALLERGENS |
CN1886156A (en) * | 2003-09-30 | 2006-12-27 | 特莱索恩儿童健康研究院 | Immunotherapy method |
DE10351471A1 (en) * | 2003-11-04 | 2005-06-09 | Ursula Prof. Dr. Wiedermann-Schmidt | Polyvalent allergy vaccine |
CA2599218C (en) * | 2005-03-18 | 2015-08-11 | Cytos Biotechnology Ag | Cat allergen conjugates and uses thereof |
US20070065468A1 (en) * | 2005-08-29 | 2007-03-22 | National University Of Singapore | Chimeric allergens for immunotherapy |
ES2307381B1 (en) * | 2006-04-12 | 2009-10-23 | Bial Industrial Farmaceutica S.A. | HYPOALLERGENIC CHEMICAL PROTEINS BELONGING TO THE FAMILY OF TRANSPORTERS OF JUDAICA PARIETARY LIPIDS USED FOR THE TREATMENT OF ALLERGIES. |
AT503690A1 (en) * | 2006-06-09 | 2007-12-15 | Biomay Ag | HYPOALLERGENIC MOLECULES |
MX2010010353A (en) | 2008-03-25 | 2010-10-05 | Bial Ind Farmaceutica S A | Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in the treatment of allergies. |
EP2295076A1 (en) * | 2009-09-10 | 2011-03-16 | Biomay Ag | Hypoallergenic hybrid polypeptides for the treatment of allergy |
ITMI20112301A1 (en) * | 2011-12-19 | 2013-06-20 | Lofarma Spa | HYPOALLERGENIC VARIATIONS OF THE ALLERGEN HIGHER PHL P 5 OF PHLEUM PRATENSE |
ES2601220T3 (en) | 2012-09-20 | 2017-02-14 | Universidad De Cartagena | Fusion proteins with representation of different allergens: vaccine proposal for mite allergy |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116612A (en) * | 1987-06-23 | 1992-05-26 | Allergy Immuno Technologies, Inc. | Immunotherapy agents for treatment of IgE mediated allergies |
US5869333A (en) * | 1988-03-23 | 1999-02-09 | University Of Melbourne | Ryegrass pollen allergen |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2596466B2 (en) * | 1990-03-03 | 1997-04-02 | アサヒビール株式会社 | DNA having transfer information of major allergen of mite and method for producing the allergen |
KR100271417B1 (en) | 1991-10-16 | 2000-12-01 | 스타세이 엘. 첸닝 | Recombitope peptides |
US5968526A (en) * | 1994-04-14 | 1999-10-19 | Immulogic Pharamaceutical Corporation | T cell epitopes of the major allergens from Dermatophagoides (house dust mite) |
SE9402089D0 (en) * | 1994-06-14 | 1994-06-14 | Rudolf Valenta | Recombinant allergen, fragments thereof, corresponding recombinant DNA molecules, vectors and hosts containing the DNA molecules, diagnostic and therapeutic uses of said allergens and fragments |
GB9516293D0 (en) | 1995-08-09 | 1995-10-11 | Immunova Ltee | Novel peptides and their use as vaccines |
GB9516760D0 (en) * | 1995-08-16 | 1995-10-18 | Sandoz Ltd | Organic compounds |
US5804201A (en) * | 1996-03-11 | 1998-09-08 | The Rockefeller University | Immunomodulatory peptides of vespid antigen 5 |
-
2000
- 2000-12-28 EP EP00128660A patent/EP1221317A1/en not_active Withdrawn
-
2001
- 2001-12-20 EP EP01130292A patent/EP1219301B1/en not_active Expired - Lifetime
- 2001-12-20 PT PT01130292T patent/PT1219301E/en unknown
- 2001-12-20 AT AT01130292T patent/ATE367826T1/en not_active IP Right Cessation
- 2001-12-20 ES ES01130292T patent/ES2287067T3/en not_active Expired - Lifetime
- 2001-12-20 DE DE60129528T patent/DE60129528T2/en not_active Expired - Lifetime
- 2001-12-20 DK DK01130292T patent/DK1219301T3/en active
- 2001-12-27 US US10/026,914 patent/US7862828B2/en not_active Expired - Fee Related
-
2002
- 2002-11-19 HK HK02108362.1A patent/HK1046648B/en not_active IP Right Cessation
-
2010
- 2010-11-26 US US12/954,821 patent/US20110150920A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116612A (en) * | 1987-06-23 | 1992-05-26 | Allergy Immuno Technologies, Inc. | Immunotherapy agents for treatment of IgE mediated allergies |
US5275814A (en) * | 1987-06-23 | 1994-01-04 | Allergy Immuno Technologies, Inc. | Allergen-thymic hormone conjugates for treatment of IgE mediated allergies |
US5869333A (en) * | 1988-03-23 | 1999-02-09 | University Of Melbourne | Ryegrass pollen allergen |
Also Published As
Publication number | Publication date |
---|---|
US20020173625A1 (en) | 2002-11-21 |
ES2287067T3 (en) | 2007-12-16 |
EP1221317A1 (en) | 2002-07-10 |
HK1046648A1 (en) | 2003-01-24 |
DK1219301T3 (en) | 2007-10-22 |
ATE367826T1 (en) | 2007-08-15 |
HK1046648B (en) | 2007-10-26 |
PT1219301E (en) | 2007-09-04 |
DE60129528D1 (en) | 2007-09-06 |
EP1219301B1 (en) | 2007-07-25 |
US7862828B2 (en) | 2011-01-04 |
EP1219301A1 (en) | 2002-07-03 |
DE60129528T2 (en) | 2008-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110150920A1 (en) | Allergy Vaccines Containing Hybrid Polypeptides | |
CN102666575B (en) | Mycobacterial vaccines | |
Vrtala et al. | Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination | |
JP2015164424A (en) | Hypoallergenic hybrid proteins of major group 1 and 2 mite allergens for use in treatment of allergies | |
CN104710512A (en) | Vaccine comprising amb a 1 peptides for use in the treatment of ragweed allergy | |
JPH06508994A (en) | Allergenic proteins and peptides from Japanese cedar pollen | |
CN114315989A (en) | Recombinant novel coronavirus protein vaccine, preparation method and application thereof | |
JPH05508847A (en) | Transfer factors and usage | |
JPH07503362A (en) | Recombitope peptide | |
AU2007246152A1 (en) | Phl p 1 allergen derivative | |
US5698204A (en) | Recombinant allergenic proteins from ragweed pollen | |
JP4253122B2 (en) | Non-anaphylactic forms of allergens and their use | |
JP6148088B2 (en) | Hypoallergenic inducible chimeric protein belonging to the family of lipid transport protein of Parietaria judaica used for allergy treatment | |
JP4745237B2 (en) | Hypoallergenic variants of the major allergens of Parietaria judaika, their use and compositions containing them | |
RU2238321C2 (en) | Dna sequence and preparing cereal crops allergen by recombinant method | |
CN115322247A (en) | Novel charge mutant antigen of coronavirus receptor binding region and application | |
ITMI20111489A1 (en) | HYPOALLERGENIC VARIATIONS OF ALLERGENE MORE MAL MAL 1 OF DOMESTIC MALUS | |
US20210163549A1 (en) | Nucleic acid for treating crustacean allergy | |
Zhang | Structure-Function Relationships of Allergens Lei Zhang and Shyam S. Mohapatra | |
WO1998059052A1 (en) | Recombinant dna which codes for epitopes of the profiline allergen useful for the diagnosis and treatment of allergies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |